HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (56) Citing Articles via Google Scholar Google Scholar Articles by Johnson, M. Articles by Rennard, S. Search for Related Content PubMed PubMed Citation Articles by Johnson, M. Articles by Rennard, S.

Alternative Mechanisms for Long-Acting ß₂-Adrenergic Agonists in COPD^*

^* From GlaxoSmithKline Research and Development (Dr. Johnson), Uxbridge, Middlesex, UK; and University of Nebraska Medical Center (Dr. Rennard), Omaha, NB.

Correspondence to: Malcolm Johnson, PhD, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom; e-mail: mj0859{at}glaxowellcome.co.uk

ß₂-Adrenergic agonists are commonly used as bronchodilators to treat patients with COPD. In addition to prolonged bronchodilation, long-acting ß₂-agonists (LABAs) exert other effects that may be of clinical relevance. These include inhibition of airway smooth-muscle cell proliferation and inflammatory mediator release, as well as nonsmooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection of the respiratory mucosa, and attenuation of neutrophil recruitment and activation. This review details the possible alternative mechanisms of action of the LABAs, salmeterol and formoterol, in COPD.

Key Words: COPD • formoterol • long-acting ß₂-adrenergic agonists • salmeterol

This article has been cited by other articles:

				S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]

				N. C. Barnes, Y.-S. Qiu, I. D. Pavord, D. Parker, P. A. Davis, J. Zhu, M. Johnson, N. C. Thomson, P. K. Jeffery, and on behalf of the SCO30005 Study Group Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 736 - 743. [Abstract] [Full Text] [PDF]

				B. J. Proskocil and A. D. Fryer {beta}2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease Proceedings of the ATS, November 1, 2005; 2(4): 305 - 310. [Abstract] [Full Text] [PDF]

				J. R. Sabater, T. A. Lee, and W. M. Abraham Comparative Effects of Salmeterol, Albuterol, and Ipratropium on Normal and Impaired Mucociliary Function in Sheep Chest, November 1, 2005; 128(5): 3743 - 3749. [Abstract] [Full Text] [PDF]

				N. A. Maris, A. F. de Vos, M. C. Dessing, C. A. Spek, R. Lutter, H. M. Jansen, J. S. van der Zee, P. Bresser, and T. van der Poll Antiinflammatory Effects of Salmeterol after Inhalation of Lipopolysaccharide by Healthy Volunteers Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 878 - 884. [Abstract] [Full Text] [PDF]

				P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]

				N.C. Thomson, R. Chaudhuri, and E. Livingston Asthma and cigarette smoking Eur. Respir. J., November 1, 2004; 24(5): 822 - 833. [Abstract] [Full Text] [PDF]

				The TORCH Study Group The TORCH (TOwards a Revolution in COPD Health) survival study protocol Eur. Respir. J., August 1, 2004; 24(2): 206 - 210. [Abstract] [Full Text] [PDF]

				C. Coraux, C. Kileztky, M. Polette, J. Hinnrasky, J.-M. Zahm, P. Devillier, S. de Bentzmann, and E. Puchelle Airway Epithelial Integrity Is Protected by a Long-Acting {beta}2-Adrenergic Receptor Agonist Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 605 - 612. [Abstract] [Full Text] [PDF]

				J. Gabrijelcic, A. Casas, R.A. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin Formoterol protects against platelet-activating factor-induced effects in asthma Eur. Respir. J., January 1, 2004; 23(1): 71 - 75. [Abstract] [Full Text] [PDF]

				D. P. Tashkin and C. B. Cooper The Role of Long-Acting Bronchodilators in the Management of Stable COPD Chest, January 1, 2004; 125(1): 249 - 259. [Abstract] [Full Text] [PDF]

				D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review JAMA, November 5, 2003; 290(17): 2301 - 2312. [Abstract] [Full Text] [PDF]

				J. A Dougherty, B. L Didur, and L. S Aboussouan Long-Acting Inhaled {beta}2-Agonists for Stable COPD Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255. [Abstract] [Full Text] [PDF]

				J.B. Soriano, J. Vestbo, N.B. Pride, V. Kiri, C. Maden, and W.C. Maier Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Eur. Respir. J., October 1, 2002; 20(4): 819 - 825. [Abstract] [Full Text] [PDF]

				N. A. Hanania, A. Sharafkhaneh, R. Barber, and B. F. Dickey {beta}-Agonist Intrinsic Efficacy: Measurement and Clinical Significance Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1353 - 1358. [Full Text] [PDF]